← Back to Search

Radiation

A for Age-Related Macular Degeneration (CABERNET Trial)

Phase 3
Waitlist Available
Led By Pravin Dugel, MD
Research Sponsored by NeoVista
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Pivotal Trial
All Individual Drugs Already Approved

Summary

The objective of the CABERNET Trial is to evaluate the safety and efficacy of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) associated with wet age-related macular degeneration (AMD). The Epi-Rad90™ Ophthalmic System treats neovascularization of retinal tissue by means of a focal, directional delivery of radiation to the target tissues in the retina. Using standard vitreoretinal surgical techniques, the sealed radiation source is placed temporarily over the retinal lesion by means of a handheld medical device.

Eligible Conditions
  • Age-Related Macular Degeneration

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: AExperimental Treatment1 Intervention
Epi-Rad90™ Ophthalmic System procedure + Lucentis
Group II: BActive Control1 Intervention
Lucentis only

Find a Location

Who is running the clinical trial?

NeoVistaLead Sponsor
2 Previous Clinical Trials
52 Total Patients Enrolled
Pravin Dugel, MDPrincipal InvestigatorRetinal Consultants of Arizona
1 Previous Clinical Trials
185 Total Patients Enrolled
Jeffrey A Nau, MMSStudy DirectorNeoVista, Inc.
1 Previous Clinical Trials
20 Total Patients Enrolled
~27 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top